

Publications from Anticancer Antibodies

01/01/2011 – 11/01/2016

In press

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, **Thomas X**, Bordessoule D, Guerci A, Lamy T, Recher C, Poire X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Ades L, Fenaux P. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. *Cancer*, In press.

Chalandon Y, **Thomas X**, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rouselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lheritier V, Chevret S, Ifrah N, Dombret H. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. *Blood*, In press.

Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, **Thomas X**. Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*, In press.

Gagneux-Brunon A, Nasri D, Terrasse R, Saune K, **Gagnieu MC**, Fresard A, Delezay O, Izopet J, Pozzetto B, Lucht F, Bourlet T. Persistent but not replicating HIV-1 cell-associated DNA in semen of long-term ART experienced men. *Curr HIV Res*, In press.

Kadia TM, **Thomas XG**, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia (AML) and higher blast counts. *Am J Hematol*, In press.

Mint Mohamed A, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, **Dumontet C**, **Cros E**, PascaleFlandrin G, Nibourel O, Preudhomme C, Michallet M, **Thomas X**, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). *Oncotarget*, In press.

Quintela A, Escuret V, Roux S, Bonnafous P, Gilis L, Barraco F, Labussiere-Wallet H, Duscastelle-Lepretre S, Nicolini FE, **Thomas X**, Chidiac C, Ferry T, Frobert E, Morisset S, Poitevin-Later F, Monneret G, Michallet M, Ader F. HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns. *J Infect*, In press.

Rampazzo C, Tozzi MG, **Dumontet C**, **Jordheim LP**. The druggability of intracellular nucleotide-degrading enzymes. *Cancer Chemother Pharmacol*, In press.

2016

Abad S, Terrada C, Trad S, Sene D, Bielefeld P, Saadoun D, **Seve P**. Management of uveomeningitis in internal medicine: Proposal for a diagnostic work-up. *Rev Med Interne*, 2016; 37(1): 25-34.

Bernard C, Frih H, Pasquet F, Kerever S, Jamilloux Y, Tronc F, Guibert B, Isaac S, Devouassoux M, Chalabreysse L, Broussolle C, Petiot P, Girard N, **Seve P**. Thymoma associated with autoimmune diseases: 85 cases and literature review. *Autoimmun Rev*, 2016; 15(1): 82-92.

Lafond M, Mestas JL, Prieur F, **Chettab K**, Geraci S, Clezardin P, Lafon C. Unseeded Inertial Cavitation for Enhancing the Delivery of Chemotherapies: A Safety Study. *Ultrasound Med Biol*, 2016; 42(1): 220-231.

2015

Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, **Thomas X**, Wierzbowska A, Jones MM, Berrak E, Kantarjian H. Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. *J Blood Med*, 2015; 6(25-29).

Barba T, Maucourt-Boulch D, Iwaz J, Bohe J, Ninet J, Hot A, Lega JC, Guerin C, Argaud L, Broussolle C, Jamilloux Y, Richard JC, **Seve P**. Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study. *Medicine (Baltimore)*, 2015; 94(51): e2318.

Bernard C, Bailly F, Craigherot F, Bancel B, Brevet M, Broussolle C, **Seve P**, Belenotti P. Asthenia, weight loss and abdominal pain in a 64-year-old woman. *Rev Med Interne*, 2015; 36(10): 706-709.

Bielefeld P, Devilliers H, Deschasse C, Saadoun D, **Seve P**, Muselier A, Creuzot-Garcher C, Besancenot JF, Bron AM. Potential of Pegylated Interferon Alpha-2a in Behcet Uveitis: A Report of Five Cases. *Ocul Immunol Inflamm*, 2015; 1-4.

Blay JY, **Tredan O**, Ray-Coquard I, Rivoire M, Mehlen P, Puisieux A, Bachelot T. Quinze questions importantes a se poser en oncologie en 2015. *Bull Cancer*, 2015; 102(6 Suppl 1): S22-26.

Boespflug A, Guerra J, **Dalle S**, Thomas L. Enhancement of Customary Dermoscopy Education With Spaced Education e-Learning: A Prospective Controlled Trial. *JAMA Dermatol*, 2015; 151(8): 847-853.

Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, **Tredan O**, Messina CG, Slaets L, Cameron D. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. *Ann Oncol*, 2015; 26(2): 325-332.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, **Thomas X**, Bordessoule D, Guerci A, Lamy T, Recher C, Poire X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Ades L, Fenaux P. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. *Cancer*, 2015; 121(14): 2393-2399.

Brisou G, Manzoni D, **Dalle S**, Felman P, Morel D, Boubaya M, Magaud JP, Baseggio L. Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells. *J Clin Lab Anal*, 2015; 29(2): 153-161.

Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczynszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, Garcia-Sanz R, Buda G, Gemignani F, Rios R, Vangsted AJ, **Dumontet C**, Martinez-Lopez J, Moreno MJ, Stepien A, Watek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzinski M, Weinhold N, Reis RM, Canzian F. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. *Int J Cancer*, 2015; 136(5): E351-358.

- Cannas G, Fattoum J, Boukhit M, **Thomas X**. Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly. *Transfus Clin Biol*, 2015; 22(5-6): 341-347.
- Cannas G, Fattoum J, Raba M, Dolange H, Barday G, Francois M, Elhamri M, Salles G, **Thomas X**. Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. *Ann Hematol*, 2015; 94(11): 1797-1806.
- Cannas G, **Thomas X**. Supportive care in patients with acute leukaemia: historical perspectives. *Blood Transfus*, 2015; 13(2): 205-220.
- Chalandon Y, **Thomas X**, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lheritier V, Chevret S, Ifrah N, Dombret H. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. *Blood*, 2015; 125(24): 3711-3719.
- Chalayer E, Bachy E, Occelli P, Weiler L, Faurie P, Ghesquieres H, Pavic M, Broussolle C, **Seve P**. Sarcoidosis and lymphoma: a comparative study. *Qjm*, 2015; 108(11): 871-878.
- Chettab K, Roux S, Mathe D, Cros-Perrial E, Lafond M, Lafon C, Dumontet C, Mestas JL**. Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents. *PLoS One*, 2015; 10(8): e0134247.
- Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marçais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, **Thomas X**, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodere F. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. *Lancet Haematol*, 2015; 2(3): e108-117.
- Chien WW, Catallo R, Chebel A, Baranger L, **Thomas X**, Bene MC, Gerland LM, Schmidt A, Beldjord K, Klein N, Escoffre-Barbe M, Leguay T, Huguet F, Larosa F, Hayette S, Plesa A, Ifrah N, Dombret H, Salles G, Chassevent A, Ffrench M. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. *Leuk Res*, 2015; 39(4): 453-461.
- Cividini F, **Cros-Perrial E**, Pesi R, Machon C, Allegrini S, Camici M, **Dumontet C, Jordheim LP**, Tozzi MG. Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5'-nucleotidase II. *Int J Biochem Cell Biol*, 2015; 65(222-229).
- Cividini F, Pesi R, Chaloin L, Allegrini S, Camici M, **Cros-Perrial E, Dumontet C, Jordheim LP**, Tozzi MG. The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor. *Biochem Pharmacol*, 2015; 94(2): 63-68.
- Cividini F, Tozzi MG, Galli A, Pesi R, Camici M, **Dumontet C, Jordheim LP**, Allegrini S. Cytosolic 5'-nucleotidase II interacts with the leucin rich repeat of NLR family member Ipaf. *PLoS One*, 2015; 10(3): e0121525.
- Couder F, Schmitt C, Treilleux I, **Tredan O**, Faure C, Carrabin N, Beurrier F, Chopin N. Axillary lymph node metastases with an occult breast: About 16 cases from a cohort of 7770 patients. *Gynecol Obstet Fertil*, 2015; 43(9): 588-592.
- Couturier MA, Huguet F, Chevallier P, Suarez F, **Thomas X**, Escoffre-Barbe M, Cacheux V, Pignon JM, Bonmati C, Sanhes L, Bories P, Daguindau E, Dorvaux V, Reman O, Frayfer J, Orvain C, Lheritier V, Ifrah N, Dombret H, Hunault-Berger M, Tanguy-Schmidt A. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction

- chemotherapy with l-asparaginase: The GRAALL experience. *Am J Hematol*, 2015; 90(11): 986-991.
- Cox DG, Heudel PE, **Tredan O**, Bachelot T. Therogenetics: transferring GWAS technology to the clinic. *Mutagenesis*, 2015; 30(2): 213-215.
- De Parisot A, Puechal X, Langrand C, Raverot G, Gil H, Perard L, Le Guenno G, Berthier S, Tschirret O, Eschard JP, Vinzio S, Guillevin L, **Seve P**. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. *Medicine (Baltimore)*, 2015; 94(16): e748.
- de Ravel MR, Alameh G, Melikian M, Mahiout Z, Emptoz-Bonneton A, **Matera EL**, Lomberget T, Barret R, Rocheblave L, Walchshofer N, Beltran S, El Jawad L, Mappus E, Grenot C, Pugeat M, **Dumontet C**, Le Borgne M, Cuilleron CY. Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells. *J Med Chem*, 2015; 58(4): 1832-1845.
- Debarbieux S, Gaspar R, Depaepe L, **Dalle S**, Balme B, Thomas L. Intraoperative diagnosis of nonpigmented nail tumours with ex vivo fluorescence confocal microscopy: 10 cases. *Br J Dermatol*, 2015; 172(4): 1037-1044.
- Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, **Thomas X**, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lheritier V, Cahn JY, Dombret H, Ifrah N. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. *Blood*, 2015; 125(16): 2486-2496.
- Dombret H, **Thomas X**, Chevallier P, Nivot E, Reitan J, Barber BL, Barlev A, Mohty M. Healthcare Burden and Economic Cost of Hospitalisation During Chemotherapy for Adult Patients with Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (ALL) in France. *Value Health*, 2015; 18(7): A443.
- Duong MN, Cleret A, Matera EL, Chettab K, Mathe D**, Valsesia-Wittmann S, Clemenceau B, **Dumontet C**. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. *Breast Cancer Res*, 2015; 17(1): 57.
- Duong MN, Matera EL, Mathe D, Evesque A**, Valsesia-Wittmann S, Clemenceau B, **Dumontet C**. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. *MAbs*, 2015; 7(1): 192-198.
- Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Lorient MA, Narjoz C, Poncet D, **Gagnieu MC**, Ged C, Broly F, Le Morvan V, Bouquie R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. *Fundam Clin Pharmacol*, 2015; 29(3): 219-237.
- Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, **Thomas X**. Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*, 2015; 15(8): 477-483.
- Fauconneau A, Pham-Ledard A, Cappellen D, Frison E, Prochazkova-Carlotti M, Parrens M, **Dalle S**, Joly P, Viraben R, Franck F, Ingen-Housz-Oro S, Giacchero D, Jullie ML, Vergier B, Merlio JP, Beylot-Barry M. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. *Br J Dermatol*, 2015; 172(6): 1547-1554.
- Febvay C, Kodjikian L, Maucort-Boulch D, Perard L, Iwaz J, Jamilloux Y, Broussolle C, Burillon C, **Seve P**. Clinical features and diagnostic evaluation of 83 biopsy-proven sarcoid uveitis cases. *Br J Ophthalmol*, 2015; 99(10): 1372-1376.
- Feurer E, Bielefeld P, Saadoun D, **Seve P**. Biologics in uveitis. *Rev Med Interne*, 2015; 36(2): 107-116.

- Foucaut AM, Berthouze SE, Touillaud M, Morelle M, Bourne-Branchu V, Kempf-Lepine AS, Carretier J, Perol D, **Tredan O**, Bachmann P, Fervers B. Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. *Cancer Nurs*, 2015; 38(4): E1-9.
- Fraison JB, **Seve P**, Dauphin C, Mahr A, Gomard-Mennesson E, Varron L, Pugnet G, Landron C, Roblot P, Oziol E, Chalhoub G, Galempoix JM, Humbert S, Humbert P, Sbidian E, Grange F, Bayrou O, Cathebras P, Morlat P, Epaulard O, Pavese P, Le Thi Huong D, Zoulim A, Stankovic K, Bachelez H, Smail A, Bachmeyer C, Granel B, Serratrice J, Brinchault G, Mekinian A, Costedoat-Chalumeau N, Bourgarit-Durand A, Puechal X, Guillevin L, Piram M, Kone-Paut I, Fain O. Kawasaki disease in adults: Observations in France and literature review. *Autoimmun Rev*, 2015;
- Gabriel L, Darcissac C, Goutelle S, **Seve P**, Vial T, de La Gastine B. Lower limb edema during valpromide treatment: case report and literature review. *Rev Med Interne*, 2015; 36(10): 698-700.
- Galmarini CM, **Tredan O**, Galmarini FC. Survivorship in untreated breast cancer patients. *Med Oncol*, 2015; 32(2): 466.
- Gerfaud-Valentin M, **Seve P**, Hot A, Broussolle C, Jamilloux Y. Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update. *Rev Med Interne*, 2015; 36(5): 319-327.
- Ginoux E, Julia F, Balme B, Thomas L, **Dalle S**. T-lymphoblastic lymphoma with cutaneous involvement. *World J Clin Cases*, 2015; 3(8): 727-731.
- Grados A, Ebbo M, Bernit E, Veit V, Mazodier K, Jean R, Coso D, Aurran-Schleinitz T, Broussais F, Bouabdallah R, Gravis G, Goncalves A, Giovaninni M, **Seve P**, Chetaille B, Gavet-Bongo F, Weitten T, Pavic M, Harle JR, Schleinitz N. Sarcoidosis Occurring After Solid Cancer: A Nonfortuitous Association: Report of 12 Cases and Review of the Literature. *Medicine (Baltimore)*, 2015; 94(28): e928.
- He J, Xiu L, De Porre P, Dass R, **Thomas X**. Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study. *Leuk Lymphoma*, 2015; 56(4): 1033-1042.
- Heiblig M, Bozzoli V, Saison J, **Thomas X**, De Croze D, Traverse-Glehen A, Cosmidis A, Chidiac C, Ferry T, Alanio A, Bienvenu AL, Dupont D, Ducastelle-Lepretre S, Michallet M, Ader F. Combined medico-surgical strategy for invasive sino-orbito-cerebral breakthrough fungal infection with *Hormoglyphiella aspergillata* in an acute leukaemia patient. *Mycoses*, 2015; 58(5): 308-312.
- Heiblig M, Elhamri M, Michallet M, **Thomas X**. Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. *World J Stem Cells*, 2015; 7(7): 1022-1038.
- Heiblig M, Elhamri M, Nicolini FE, Wattel E, Michallet M, Salles G, **Thomas X**. Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study. *Clin Lymphoma Myeloma Leuk*, 2015; 15 Suppl(S7-13).
- Jamilloux I, Valeyre D, Lortholary O, Bernard C, Kerever S, Lelievre L, Neel A, Broussolle C, **Seve P**. The spectrum of opportunistic diseases complicating sarcoidosis. *Autoimmun Rev*, 2015; 14(1): 64-74.
- Jamilloux Y, Gerfaud-Valentin M, Henry T, **Seve P**. Treatment of adult-onset Still's disease: a review. *Ther Clin Risk Manag*, 2015; 11(33-43).
- Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, **Seve P**. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. *Immunol Res*, 2015; 61(1-2): 53-62.
- Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondreville ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J,

- Flechon A, Le Cesne A, Penel N, **Tredan O**, Blay JY. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. *Oncotarget*, 2015; 6(28): 26388-26399.
- Jobard E, Blanc E, Negrier S, Escudier B, Gravis G, Chevreau C, Elena-Herrmann B, **Tredan O**. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. *Br J Cancer*, 2015; 113(8): 1148-1157.
- Jordheim LP**, Puy JY, **Cros-Perrial E**, Peyrottes S, Lefebvre I, Perigaud C, **Dumontet C**. Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models. *Anal Bioanal Chem*, 2015; 407(19): 5747-5758.
- Jordheim LP**, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Demangel D, Salles GA, **Dumontet C**. Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. *Haematologica*, 2015; 100(5): e204-206.
- Jouary T, Kubica E, **Dalle S**, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C. Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma. *Acta Derm Venereol*, 2015; 95(7): 835-840.
- Kadia TM, **Thomas XG**, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. *Am J Hematol*, 2015; 90(7): E139-141.
- Le Jeune C, **Thomas X**. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. *Eur J Haematol*, 2015; 94(2): 99-108.
- Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, Campone M, **Tredan O**, Massiani MA, Mauborgne C, Armanet S, Servant N, Bieche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *Lancet Oncol*, 2015; 16(13): 1324-1334.
- Lesort C, Debarbieux S, Duru G, **Dalle S**, Poulhalon N, Thomas L. Dermoscopic Features of Onychomatricoma: A Study of 34 Cases. *Dermatology*, 2015; 231(2): 177-183.
- Machon C, Bordes C, **Cros-Perrial E**, Clement Y, **Jordheim LP**, Lanteri P, Guitton J. Use of designed experiments for the improvement of pre-analytical workflow for the quantification of intracellular nucleotides in cultured cell lines. *J Chromatogr A*, 2015; 1405(116-125).
- Marton Z, Guillon R, Krimm I, Preeti, Rahimova R, Egron D, **Jordheim LP**, Aghajari N, **Dumontet C**, Perigaud C, Lionne C, Peyrottes S, Chaloin L. Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach. *J Med Chem*, 2015; 58(24): 9680-9696.
- Michallet M, Sobh M, Serrier C, Morisset S, Labussiere H, Ducastelle S, Barraco F, Gilis L, **Thomas X**, Nicolini FE. Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings. *Leuk Lymphoma*, 2015; 56(4): 999-1003.
- Nicolini FE, Etienne G, Dubruille V, Roy L, Hugué F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Ame S, **Gagnieu MC**, Pivot

- C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. *Lancet Haematol*, 2015; 2(1): e37-46.
- Pertesi M, Galia P, Nazaret N, Vallee M, Garderet L, Leleu X, Avet-Loiseau H, Foll M, Byrnes G, Lachuer J, McKay JD, **Dumontet C**. Rare Circulating Cells in Familial Waldenstrom Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. *PLoS One*, 2015; 10(9): e0136505.
- Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, **Thomas X**, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terre C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. *Haematologica*, 2015; 100(5): e196-199.
- Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, **Dumontet C**, **Thomas X**. Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. *Leuk Lymphoma*, 2015; 56(3): 622-629.
- Poglio S, Cahu X, Uzan B, Besnard-Guerin C, Lapillonne H, Leblanc T, Baruchel A, Landman-Parker J, Petit A, **Baleyrier F**, Amsellem S, Baud V, Ballerini P, Pflumio F. Rapid childhood T-ALL growth in xenograft models correlates with mature phenotype and NF-kappaB pathway activation but not with poor prognosis. *Leukemia*, 2015; 29(4): 977-980.
- Poulalhon N, **Dalle S**, Balme B, Thomas L. Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib. *Dermatology*, 2015; 230(2): 101-104.
- Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, **Tredan O**, Chabaud S, Treilleux I, Corbo L, Romancer ML. Role of JMJD6 in Breast Tumourigenesis. *PLoS One*, 2015; 10(5): e0126181.
- Pradat P, Virlogeux V, Maynard M, Leclercq M, Hatu G, Amiri M, Lebosse F, Miaillhes P, Zoulim F, **Gagnieu MC**, Bailly F. Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy. *Hepat Mon*, 2015; 15(9): e28879.
- Ranchon F, Boespflug A, Rioufol C, Schwiertz V, Thomas L, **Dalle S**. New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies. *Anticancer Agents Med Chem*, 2015; 15(4): 461-467.
- Ravandi F, Pigneux A, DeAngelo DJ, Raffoux E, Delaunay J, **Thomas X**, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith BD. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. *Blood Cancer J*, 2015; 5(e375).
- Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, **Thomas X**, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. *Lancet Oncol*, 2015; 16(9): 1025-1036.
- Rios R, Lupianez CB, Campa D, Martino A, Martinez-Lopez J, Martinez-Bueno M, Varkonyi J, Garcia-Sanz R, Jamroziak K, **Dumontet C**, Cayuela AJ, Wetek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczynski A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. Type 2 diabetes-related

- variants influence the risk of developing multiple myeloma: results from the IMMENSE consortium. *Endocr Relat Cancer*, 2015; 22(4): 545-559.
- Saison J, Costedoat-Chalumeau N, Maucourt-Boulch D, Iwaz J, Marignier R, Cacoub P, Vital-Durand D, Hot A, Tebib J, Aumaitre O, Schleinitz N, Sarrot-Reynaud F, Broussolle C, **Seve P**. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. *Lupus*, 2015; 24(1): 74-81.
- Sarkissian L, Thomas L, **Dalle S**. Longitudinal melanonychia. *Ann Dermatol Venereol*, 2015; 142(10): 607-608.
- Saunier J, Debarbieux S, Jullien D, Garnier L, **Dalle S**, Thomas L. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. *Dermatology*, 2015; 230(2): 97-100.
- Seve P**, Kodjikian L, Adelaide L, Jamilloux Y. Uveitis in adults: What do rheumatologists need to know? *Joint Bone Spine*, 2015; 82(5): 308-314.
- Smol T, Nibourel O, Marceau-Renaut A, Celli-Lebras K, Berthon C, Quesnel B, Boissel N, Terre C, **Thomas X**, Castaigne S, Dombret H, Preudhomme C, Renneville A. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. *Leuk Res*, 2015; 39(12): 1443-1447.
- Tawana K, Wang J, Renneville A, Bodor C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, **Thomas X**, Mialou V, Dohner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. *Blood*, 2015; 126(10): 1214-1223.
- Theillac C, Thomas L, **Dalle S**. Lentigo maligna. *Ann Dermatol Venereol*, 2015; 142(11): 714-715.
- Thomas X**. Acute myeloid leukemia in the pregnant patient. *Eur J Haematol*, 2015; 95(2): 124-136.
- Thomas X**. Novel approaches to pediatric leukemia treatment. *Expert Rev Anticancer Ther*, 2015; 15(7): 811-828.
- Thomas X**. Understanding leukemic hematopoiesis as a complex adaptive system. *World J Stem Cells*, 2015; 7(9): 1145-1149.
- Thomas X**. Blinatumomab: a new era of treatment for adult ALL? *Lancet Oncol*, 2015; 16(1): 6-7.
- Thomas X**. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL? *Lancet Oncol*, 2015; 16(15): 1451-1453.
- Thonnon C, Faure C, Chopin N, Beurrier F, Quoc CH, **Tredan O**, Carrabin N. Metastatic screening before adjuvant chemotherapy in breast cancer. *Bull Cancer*, 2015; 102(5): 411-416.
- Tredan O**, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, Aloe A, Roche H. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. *Clin Breast Cancer*, 2015; 15(1): 8-15.
- Tredan O**, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barriere J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthelemy P. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. *Target Oncol*, 2015; 10(2): 189-198.
- Tredan O**, Menetrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronese E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Perol D, Blay JY, Caux C.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. *Ann Oncol*, 2015; 26(7): 1353-1362.

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, **Seve P**, Sibia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: Multicenter study of 124 patients. *J Autoimmun*, 2015; 62(67-74).

Vanacker H, Bally O, Kassem L, **Tredan O**, Heudel P, Bachelot T. Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015. *Bull Cancer*, 2015; 102(6 Suppl 1): S47-52.

Vilquin P, Cohen P, Maudelonde T, **Tredan O**, Treilleux I, Bachelot T, Heudel PE. New therapeutical strategies in metastatic hormone-dependent breast cancer. *Bull Cancer*, 2015; 102(4): 367-380.

Wach J, Maucourt-Boulch D, Kodjikian L, Iwaz J, Broussolle C, **Seve P**. Acute anterior uveitis and undiagnosed spondyloarthritis: usefulness of Berlin criteria. *Graefes Arch Clin Exp Ophthalmol*, 2015; 253(1): 115-120.

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, **Dumontet C**, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczynski A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Juul Vangsted A, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nat Commun*, 2015; 6(10203).

Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, **Dumontet C**, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczynski A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nat Commun*, 2015; 6(7539).

2014

Beldjord K, Chevret S, Asnafi V, Hugué F, Boulland ML, Leguay T, **Thomas X**, Cayuela JM, Gardel N, Chalandon Y, Boissel N, Schaefer B, Delabesse E, Cave H, Chevallier P, Buzyn A, Fest T, Reman O, Vernant JP, Lheritier V, Bene MC, Lafage M, Macintyre E, Ifrah N, Dombret H. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. *Blood*, 2014; 123(24): 3739-3749.

Bidard FC, **Tredan O**. Trends in cancer-targeted antibody-drug conjugates. *Target Oncol*, 2014; 9(1): 1-8.

Bolotte A, Vial T, Bricca P, Bernard C, Broussolle C, **Seve P**. Drug-induced immune haemolytic anemia: a retrospective study of 10 cases. *Rev Med Interne*, 2014; 35(12): 779-789.

Bond J, Bergon A, Durand A, Tigaud I, **Thomas X**, Asnafi V, Spicuglia S, Macintyre E. Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. *Blood*, 2014; 124(19): 3023-3025.

- Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Lorient MA, Poncet D, **Gagnieu MC**, Ged C, Broly F, Le Morvan V, Bouquie R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C. Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan. *Bull Cancer*, 2014; 101(6): 533-553.
- Breton AL, Amini-Adle M, Duru G, Poulalhon N, **Dalle S**, Thomas L. Overview of the use of dermoscopy in academic and non-academic hospital centres in France: a nationwide survey. *J Eur Acad Dermatol Venereol*, 2014; 28(9): 1207-1213.
- Carrera C, Bennassar A, Ishioka P, **Dalle S**, Vilalta A, Fuertes I, Alos L, Thomas L, Puig S, Malveyh J. Desmoplastic melanoma on the nose: electrochemotherapy as an alternative treatment to local advanced disease. *J Eur Acad Dermatol Venereol*, 2014; 28(4): 424-432.
- Chaabane F, Krifa M, **Matera E**, Loussaief A, Dijoux-Franca MG, Ghedira K, **Dumontet C**, Chekir-Ghedira L. In vitro antileukaemic activity of extracts from *Daphne gnidium* leaves against sensitive and multidrug resistant K562/R7 cells. *Tumour Biol*, 2014; 35(9): 8991-8998.
- Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, Cohen-Aubart F, Wislez M, Cadranet J, Housset B, Lloret-Linares C, **Seve P**, Pagnoux C, Abad S, Camuset J, Bienvenu B, Duruisseaux M, Hachulla E, Arlet JB, Hamidou M, Mahr A, Resche-Rigon M, Brun AL, Grenier P, Cacoub P, Saadoun D. Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: A Series of 49 Patients and Review of the Literature. *Medicine (Baltimore)*, 2014; 93(24): 340-349.
- de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garcia S, d'Incan M, Dereure O, **Dalle S**, Domp Martin A, Suarez F, Battistella M, Vignon-Pennamen MD, Rivet J, Adamski H, Brice P, Francois S, Lissandre S, Turlure P, Wierzbicka-Hainaut E, Brissot E, Dulery R, Servais S, Ravinet A, Tabrizi R, Ingen-Housz-Oro S, Joly P, Socie G, Bagot M. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. *Haematologica*, 2014; 99(3): 527-534.
- Debarbieux S, **Dalle S**, Depaepe L, Jeannot PY, Poulalhon N, Thomas L. Extramammary Paget's disease of the scalp: examination by in vivo and ex vivo reflectance confocal microscopy. *Skin Res Technol*, 2014; 20(1): 124-126.
- Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallee F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, **Dumontet C**, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. *Clin Cancer Res*, 2014; 20(17): 4574-4583.
- Delaunay J, Moulin C, **Dalle S**, Thomas L. Superficial basal cell carcinoma versus nodular basal cell carcinoma. *Ann Dermatol Venereol*, 2014; 141(4): 312-313.
- Dhilly M, Guillouet S, Patin D, Fillesoye F, Abbas A, Gourand F, Tirel O, Galateau F, MacKenzie ET, **Dumontet C**, Leporrier M, Barre L. 2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models. *Mol Imaging Biol*, 2014; 16(1): 118-126.
- Galmarini CM, **Tredan O**, Galmarini FC. Concomitant resistance and early-breast cancer: should we change treatment strategies? *Cancer Metastasis Rev*, 2014; 33(1): 271-283.
- Gerfaud-Valentin M, Hot A, Huissoud C, Durieu I, Broussolle C, **Seve P**. Adult-onset Still's disease and pregnancy: about ten cases and review of the literature. *Rheumatol Int*, 2014; 34(6): 867-871.
- Gerfaud-Valentin M, Jamilloux Y, Iwaz J, **Seve P**. Adult-onset Still's disease. *Autoimmun Rev*, 2014; 13(7): 708-722.

- Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, Broussolle C, **Seve P**. Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. *Medicine (Baltimore)*, 2014; 93(2): 91-99.
- Gerfaud-Valentin M, **Seve P**, Iwaz J, Gagnard A, Broussolle C, Durieu I, Ninet J, Hot A. Myocarditis in adult-onset Still's disease. *Medicine*, 2014; 93(280-289).
- Gilis L, Morisset S, Billaud G, Ducastelle-Lepretre S, Labussiere-Wallet H, Nicolini FE, Barraco F, Detrait M, **Thomas X**, Tedone N, Sobh M, Chidiac C, Ferry T, Salles G, Michallet M, Ader F. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*, 2014; 49(5): 664-670.
- Graeppi-Dulac J, Vlaeminck-Guillem V, Perier-Muzet M, **Dalle S**, Orgiazzi J. Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis. *Eur J Endocrinol*, 2014; 170(6): R253-262.
- Grange F, Joly P, Barbe C, Bagot M, **Dalle S**, Ingen-Housz-Oro S, Maubec E, D'Incan M, Ram-Wolff C, Dalac S, Templier I, Esteve E, Quereux G, Machet L, Leduc M, Dereure O, Laroche L, Saiag P, Vergier B, Beylot-Barry M. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. *JAMA Dermatol*, 2014; 150(5): 535-541.
- Gutierrez A, Pan L, Groen RW, **Baleyrier F**, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, Poglio S, Uzan B, Clemons P, VerPlank L, An F, Burbank J, Norton S, Tolliday N, Steen H, Weng AP, Yuan H, Bradner JE, Mitsiades C, Look AT, Aster JC. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. *J Clin Invest*, 2014; 124(2): 644-655.
- Hatu G, Bailly F, Pourcelot E, Pradat P, Mialhes P, Maynard M, Parant F, Chiarello P, Livrozet JM, Zoulim F, **Gagnieu MC**. Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. *BMC Infect Dis*, 2014; 14(150).
- Hoelt P, **Dalle S**, Thomas L. Cutaneous metastases of melanoma. *Ann Dermatol Venereol*, 2014; 141(10): 640-642.
- Hospital MA, Prebet T, Bertoli S, **Thomas X**, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. *Blood*, 2014; 124(8): 1312-1319.
- Jamilloux Y, Kodjikian L, Broussolle C, **Seve P**. Sarcoidosis and uveitis. *Autoimmun Rev*, 2014; 13(8): 840-849.
- Jamilloux Y, Neel A, Lecouffe-Desprets M, Fevre A, Kerever S, Guillon B, Bouvry D, Varron L, Redares C, Dominique S, Roux M, Chapelon-Abrie C, Valeyre D, Ducray F, Bernard C, Broussolle C, Hamidou M, **Seve P**. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. *Neurology*, 2014; 82(15): 1307-1313.
- Jamilloux Y, **Seve P**, Henry T. Inflammasomes in human diseases. *Rev Med Interne*, 2014; 35(11): 730-741.
- Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B, **Tredan O**. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. *Cancer Lett*, 2014; 343(1): 33-41.
- Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, Dumontet C**. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. *Clin Exp Pharmacol Physiol*, 2014; 41(10): 817-824.

- Julia F, **Dalle S**, Duru G, Balme B, Vergier B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L, Dalac S, Delattre C, Dechelotte P, Courville P, Carlotti A, De Muret A, Fraitag S, Levy A, Mitchell A, Petrella T. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. *Am J Surg Pathol*, 2014; 38(5): 673-680.
- Karam M, Thenoz M, Capraro V, Robin JP, Pinatel C, Lancon A, Galia P, Sibon D, **Thomas X**, Ducastelle-Lepretre S, Nicolini F, El-Hamri M, Chelghoun Y, Wattel E, Mortreux F. Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias. *Neoplasia*, 2014; 16(1): 21-30.
- Le Jeune C, Bertoli S, Elhamri M, Vergez F, Borel C, Huguette F, Michallet M, **Dumontet C**, Recher C, **Thomas X**. Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. *Leuk Lymphoma*, 2014; 55(4): 855-862.
- Le Tourneau C, Paoletti X, Servant N, Bieche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, **Tredan O**, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M. Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. *Br J Cancer*, 2014; 111(1): 17-24.
- Leal C, Le Roux K, Rahmi A, Varron L, Broussolle C, Denis P, Kodjikian L, **Seve P**. Scleritis, clinical features, etiologies and treatment: a case series of 32 patients. *Rev Med Interne*, 2014; 35(8): 491-497.
- Lefaucheur R, Ahtoy P, Bouwyn JP, Maltete D, Bourre B, Jamilloux Y, Neel A, Broussolle C, Hamidou M, **Seve P**. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. *Neurology*, 2014; 83(14): 1301-1302.
- Lefevre A, Thomas L, **Dalle S**. Negative pigment network. *Ann Dermatol Venereol*, 2014; 141(3): 237-238.
- Legeay AL, Thomas L, **Dalle S**. Subungual melanoma. *Ann Dermatol Venereol*, 2014; 141(1): 69-70.
- Leroy S, Gaudebout N, Lanteme P, **Seve P**. Recurrent pericarditis as an initial manifestation of Wegener's granulomatosis. *Ann Cardiol Angeiol (Paris)*, 2014; 63(1): 48-50.
- Machon C, **Jordheim LP**, Puy JY, Lefebvre I, **Dumontet C**, Guitton J. Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem*, 2014; 406(12): 2925-2941.
- Maillet L, Chopin N, Treilleux I, Bachelot T, **Tredan O**, Faure C, Caux C, Beurrier F. Spontaneous regression of breast cancer after biopsy. About two cases. *Gynecol Obstet Fertil*, 2014; 42(4): 269-272.
- Marijon A, Bonnot G, Fourier A, Bringer C, Lavoignat A, **Gagnieu MC**, Bienvenu AL, Picot S. Efficacy of intranasal administration of artesunate in experimental cerebral malaria. *Malar J*, 2014; 13(501).
- Martino A, Campa D, Jurczynski A, Martinez-Lopez J, Moreno MJ, Varkonyi J, **Dumontet C**, Garcia-Sanz R, Gemignani F, Jamrozik K, Stepień A, Jacobsen SE, Andersen V, Jurado M, Landi S, Rossi AM, Lesueur F, Marques H, Dudzinski M, Watek M, Moreno V, Orciuolo E, Petrini M, Reis RM, Rios R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F. Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. *Cancer Epidemiol Biomarkers Prev*, 2014; 23(4): 670-674.

- Mayer J, Arthur C, Delaunay J, Mazur G, **Thomas XG**, Wierzbowska A, Ravandi F, Berrak E, Jones M, Li Y, Kantarjian HM. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. *BMC Cancer*, 2014; 14(69).
- Mendes-da-Cruz DA, Brignier AC, Asnafi V, **Baleyrier F**, Messias CV, Lepelletier Y, Bedjaoui N, Renand A, Smaniotto S, Canioni D, Milpied P, Balabanian K, Bouso P, Lepretre S, Bertrand Y, Dombret H, Ifrah N, Dardenne M, Macintyre E, Savino W, Hermine O. Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. *PLoS One*, 2014; 9(7): e103405.
- Meurillon M, Marton Z, Hospital A, **Jordheim LP**, Bejaud J, Lionne C, **Dumontet C**, Perigaud C, Chaloin L, Peyrottes S. Structure-activity relationships of beta-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: Synthesis, in vitro evaluation and molecular modeling studies. *Eur J Med Chem*, 2014; 77(18-37).
- Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, **Tredan O**, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammour KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. *Ann Oncol*, 2014; 25(8): 1570-1577.
- Pallure V, Frouin E, Petrella T, Depaepe L, **Dalle S**, Dereure O. Cutaneous indeterminate cell histiocytosis: two new observations including a case with paraneoplastic-like evolution. *Eur J Dermatol*, 2014; 24(4): 505-506.
- Pan H, Gazarian A, Buff S, Solla F, **Gagnieu MC**, Leveneur O, Watrelot-Virieux D, Morisset S, Sobh M, Michallet MC, Roger T, Dubernard JM, Michallet M. Oral cyclosporine A in neonatal swines for transplantation studies. *Immunopharmacol Immunotoxicol*, 2014; 1-7.
- Pan H, Gazarian A, Fourier A, **Gagnieu MC**, Leveneur O, Sobh M, Michallet MC, Buff S, Roger T, Dubernard JM, Michallet M. Short-term Pharmacokinetic Study of Mycophenolate Mofetil in Neonatal Swine. *Transplant Proc*, 2014; 46(10): 3620-3628.
- Papo M, Bielefeld P, Vallet H, **Seve P**, Wechsler B, Cacoub P, Le Hoang P, Papo T, Bodaghi B, Saadoun D. Tocilizumab in severe and refractory non-infectious uveitis. *Clin Exp Rheumatol*, 2014; 32(4 Suppl 84): S75-79.
- Parra D, Mekki Y, Durieu I, Broussolle C, **Seve P**. Clinical and biological manifestations in primary parvovirus B19 infection in immunocompetent adult: a retrospective study of 26 cases. *Rev Med Interne*, 2014; 35(5): 289-296.
- Perier-Muzet M, Thomas L, **Dalle S**. Safety and Management of New Primary Melanomas During Receipt of BRAF Inhibitors. *J Clin Oncol*, 2014; 32(28): 3202-3203.
- Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier PP, Duru G, Depaepe L, Balme B, **Dalle S**. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. *J Invest Dermatol*, 2014; 134(5): 1351-1358.
- Peron J, Depaepe L, Decroze D, Jaouen A, **Dalle S**, Balme B. Atypical fibroxanthoma. *Ann Dermatol Venerol*, 2014; 141(12): 786-789.
- Rahme R, **Thomas X**, Recher C, Vey N, Delaunay J, Deconinck E, Hirsch P, Bordessoule D, Micol JB, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau JP, Hunault-Berger M, Fegueux N, Raffoux E, Dombret H, Degos L, Fenaux P, Ades L. Early death in acute promyelocytic leukemia

- (APL) in French centers: a multicenter study in 399 patients. *Leukemia*, 2014; 28(12): 2422-2424.
- Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C.** Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. *Leuk Lymphoma*, 2014; 55(1): 188-190.
- Rizzieri D, Vey N, **Thomas X**, Huguet-Rigal F, Schlenk RF, Krauter J, Kindler T, Gjertsen BT, Blau IW, Jacobsen TF, Johansen M, Bergeland T, Gianella-Borradori A, Krug U. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. *Leuk Lymphoma*, 2014; 55(9): 2114-2119.
- Robine A, Hot A, Maucourt-Boulch D, Iwaz J, Broussolle C, **Seve P.** Fever of unknown origin in the 2000s: evaluation of 103 cases over eleven years. *Presse Med*, 2014; 43(9): e233-240.
- Roux S, Ferry T, Chidiac C, Bouaziz A, Ninet J, Perard L, Farhat F, Broussolle C, **Seve P.** Infectious thoracic aortic aneurysms: 7 cases and literature review. *Rev Med Interne*, 2014; 35(6): 357-364.
- Saison J, Berger F, Lebosse F, Audoual R, **Thomas X**, Michallet M. Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia. *Am J Case Rep*, 2014; 15(13-17).
- Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, **Tredan O**, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. *Med Oncol*, 2014; 31(8): 76.
- Surinach C, Balme B, Thomas L, **Dalle S.** Melanoma in regression. *Ann Dermatol Venereol*, 2014; 141(2): 147-149.
- Thepot S, Itzykson R, Seegers V, Recher C, Raffoux E, Quesnel B, Delaunay J, Cluzeau T, Marfaing Koka A, Stamatoullas A, Chaury MP, Dartigeas C, Cheze S, Banos A, Morel P, Plantier I, Taksin AL, Marolleau JP, Pautas C, **Thomas X**, Isnard F, Beve B, Chait Y, Guerci A, Vey N, Dreyfus F, Ades L, Ifrah N, Dombret H, Fenaux P, Gardin C. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. *Am J Hematol*, 2014; 89(4): 410-416.
- Thomas X.** Current indications of allogeneic stem cell transplant in adults with acute myeloid leukemia. *Bull Cancer*, 2014; 101(9): 856-865.
- Thomas XG**, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk*, 2014; 14(1): 68-72.
- Uzan B, Poglio S, Gerby B, Wu CL, Gross J, Armstrong F, Calvo J, Cahu X, Deswarte C, Dumont F, Passaro D, Besnard-Guerin C, Leblanc T, Baruchel A, Landman-Parker J, Ballerini P, Baud V, Ghysdael J, **Baleyrier F**, Porteu F, Pflumio F. Interleukin-18 produced by bone marrow-derived stromal cells supports T-cell acute leukaemia progression. *EMBO Mol Med*, 2014; 6(6): 821-834.
- Willemze R, Suci S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrere F, Sr., Magro D, Sica S, Cantore N, Beksac M, Berneman Z, **Thomas X**, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeyer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. *J Clin Oncol*, 2014; 32(3): 219-228.

2013

- Adam A, Thomas L, Bories N, Zaharia D, Balme B, Freymond N, **Dalle S**. Sarcoidosis associated with vemurafenib. *Br J Dermatol*, 2013; 169(1): 206-208.
- Ades L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, **Thomas X**, Quesnel B, Cassinat B, Chomienne C, Dombret H, Degos L, Fenaux P. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. *Am J Hematol*, 2013; 88(7): 556-559.
- Almouazen E, Bourgeois S, **Jordheim LP**, Fessi H, Briancon S. Nano-encapsulation of Vitamin D3 Active Metabolites for Application in Chemotherapy: Formulation Study and in Vitro Evaluation. *Pharm Res*, 2013; 30(4): 1137-1146.
- Amadori S, Suci S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lubbert M, **Thomas X**, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). *J Clin Oncol*, 2013; 31(35): 4424-4430.
- Bachelot T, **Tredan O**. Targeted treatments for breast cancer: a step forward. *Lancet Oncol*, 2013; 14(6): 438-439.
- Bernard C, Kodjikian L, Bancel B, Isaac S, Broussolle C, **Seve P**. Ocular sarcoidosis: when should labial salivary gland biopsy be performed? *Graefes Arch Clin Exp Ophthalmol*, 2013; 251(3): 855-860.
- Bernard C, Maucort-Boulch D, Varron L, Charlier C, Sitbon K, Freymond N, Bouhour D, Hot A, Masquelet AC, Valeyre D, Costedoat-Chalumeau N, Etienne M, Gueit I, Jouneau S, Delaval P, Mouthon L, Pouget J, Serratrice J, Brion JP, Vaylet F, Bremont C, Chennebault JM, Jaffuel S, Broussolle C, Lortholary O, **Seve P**. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. *Qjm*, 2013; 106(6): 523-539.
- Bernard J, Poulalhon N, Argenziano G, Debarbieux S, **Dalle S**, Thomas L. Dermoscopy of dermatofibrosarcoma protuberans: a study of 15 cases. *Br J Dermatol*, 2013; 169(1): 85-90.
- Boyer-Provera E, Rossi A, Oriol L, **Dumontet C**, Plesa A, Berguiga L, Elezgaray J, Arneodo A, Argoul F. Wavelet-based decomposition of high resolution surface plasmon microscopy V(Z) curves at visible and near infrared wavelengths. *Opt Express*, 2013; 21(6): 7456-7477.
- Brackers de Hugo L, Ffrench M, Broussolle C, **Seve P**. Granulomatous lesions in bone marrow: clinicopathologic findings and significance in a study of 48 cases. *Eur J Intern Med*, 2013; 24(5): 468-473.
- Braun RP, Thomas L, Dusza SW, Gaide O, Menzies S, **Dalle S**, Blum A, Argenziano G, Zalaudek I, Kopf A, Rabinovitz H, Oliviero M, Perrinaud A, Cabo H, Pizzichetta M, Pozo L, Langford D, Tanaka M, Saida T, Perusquia Ortiz AM, Kreusch J, De Giorgi V, Piccolo D, Grichnik JM, Kittler H, Puig S, Malvey J, Seidenari S, Stanganelli I, French L, Marghoob AA. Dermoscopy of acral melanoma: a multicenter study on behalf of the international dermoscopy society. *Dermatology*, 2013; 227(4): 373-380.
- Buron F, Malvezzi P, Villar E, Chauvet C, Janbon B, Denis L, Brunet M, Daoud S, Cahen R, Pouteil-Noble C, **Gagnieu MC**, Bienvenu J, Bayle F, Morelon E, Thauinat O. Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study. *PLoS One*, 2013; 8(1): e53078.

- Carrabin N, Treilleux I, Meeus P, **Tredan O**, Ray-Coquard I. Primary ovarian borderline tumor in the inguinal lymph node. *Int J Gynecol Pathol*, 2013; 32(2): 167-170.
- Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, **Dalle S**, Bernard P, Woronoff AS, Grange F. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. *JAMA Dermatol*, 2013; 149(10): 1150-1157.
- Clerc J, Sunyach MP, Duruisseaux M, Mignotte H, Bajard A, **Tredan O**, Arnaud A. Regional recurrence of triple-negative breast cancer: Interest of systematic adjuvant lymph node irradiation? *Gynecol Obstet Fertil*, 2013; 41(2): 90-95.
- Conde Montero E, Thomas L, **Dalle S**. Pigmented basal cell carcinoma. *Ann Dermatol Venereol*, 2013; 140(6-7): 485-486.
- Dalle S**, Poulalhon N, Debarbieux S, Thomas L. Second primary melanomas on treatment with vemurafenib. *Br J Dermatol*, 2013; 168(4): 887-888.
- Dalle S**, Poulalhon N, Debarbieux S, Zaharia D, Mihm MC, Lacouture ME, Rosen A, Marghoob AA, Busam KJ, Depaepe L, Bringuier PP, Richez P, Baurain JF, Bressac-de Paillerets B, Balme B, Thomas L. Tracking of second primary melanomas in vemurafenib-treated patients. *JAMA Dermatol*, 2013; 149(4): 488-490.
- Debarbieux S, **Dalle S**, Depaepe L, Poulalhon N, Balme B, Thomas L. Second primary melanomas treated with BRAF blockers: study by reflectance confocal microscopy. *Br J Dermatol*, 2013; 168(6): 1230-1235.
- Debarbieux S, Depaepe L, Poulalhon N, Balme B, **Dalle S**, Thomas L. Reflectance confocal microscopy accurately discriminates between benign and malignant melanocytic lesions exhibiting a 'dermoscopic island'. *J Eur Acad Dermatol Venereol*, 2013; 27(2): e159-165.
- Debarbieux S, Depaepe L, Poulalhon N, **Dalle S**, Balme B, Thomas L. Reflectance confocal microscopy characteristics of eight cases of pustular eruptions and histopathological correlations. *Skin Res Technol*, 2013; 19(1): e444-452.
- Deshayes E, Le Berre JP, Jouanneau E, Vasiljevic A, Raverot G, **Seve P**. 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. *Clin Nucl Med*, 2013; 38(1): e50-52.
- Doleans-Jordheim A, Veron JB, Fendrich O, Bergeron E, Montagut-Romans A, Wong YS, Furdui B, Freney J, **Dumontet C**, Boumendjel A. 3-Aryl-4-methyl-2-quinolones targeting multiresistant *Staphylococcus aureus* bacteria. *ChemMedChem*, 2013; 8(4): 652-657.
- Dumortier J, Guillaud O, **Gagnieu MC**, Janbon B, Juillard L, Morelon E, Leroy V. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? *J Clin Virol*, 2013; 56(2): 146-149.
- Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin ML, **Thomas X**, Tiberghien P, Simpson E, Rigal D, Scott D. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone. *J Immunol*, 2013; 190(1): 184-194.
- Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C, **Seve P**. Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. *Joint Bone Spine*, 2013; 80(6): 645-649.
- Falandry C, Weber B, Savoye AM, Tinquaut F, **Tredan O**, Sevin E, Stefani L, Savinelli F, Atlassi M, Salvat J, Pujade-Lauraine E, Freyer G. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. *Ann Oncol*, 2013; 24(11): 2808-2813.

- Fernandes Massa A, Debarbieux S, Depaepe L, **Dalle S**, Balme B, Thomas L. Pigmented squamous cell carcinoma of the nail bed presenting as a melanonychia striata: diagnosis by perioperative reflectance confocal microscopy. *Br J Dermatol*, 2013; 169(1): 198-199.
- Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, **Thomas X**, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terre C, Fenaux P, Bordessoule D, Celli-Lebras K, Castaigne S, Dombret H. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. *J Clin Oncol*, 2013; 31(3): 321-327.
- Goutelle S, Baudry T, **Gagnieu MC**, Boibieux A, Livrozet JM, Peyramond D, Chidiac C, Tod M, Ferry T. Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients. *Antimicrob Agents Chemother*, 2013; 57(1): 517-523.
- Gupta V, Richards S, Rowe J, with **Thomas X**. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. *Blood*, 2013; 121(2): 339-350.
- Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, **Duong MN**, **Reslan L**, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, **Dumontet C**, Umana P, Niederfellner G, Bacac M, Klein C. Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models. *Mol Cancer Ther*, 2013; 12(10): 2031-2042.
- Honorat M, Terreux R, Falson P, Di Pietro A, **Dumontet C**, Payen L. Localization of putative binding sites for cyclic guanosine monophosphate and the anti-cancer drug 5-fluoro-2'-deoxyuridine-5'-monophosphate on ABCC11 in silico models. *BMC Struct Biol*, 2013; 13(7).
- Jamilloux Y, Bonnefoy M, Valeyre D, Varron L, Broussolle C, **Seve P**. Elderly-onset sarcoidosis: prevalence, clinical course, and treatment. *Drugs Aging*, 2013; 30(12): 969-978.
- Jordheim LP**, Barakat KH, Heinrich-Balard L, **Matera EL**, **Cros-Perrial E**, **Bouledrak K**, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszyński J, **Dumontet C**. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. *Mol Pharmacol*, 2013; 84(1): 12-24.
- Jordheim LP, Chaloin L. Therapeutic Perspectives for cN-II in Cancer. *Curr Med Chem*, 2013; 20(34): 4292-4303.
- Jordheim LP**, **Dumontet C**. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? *Biomark Med*, 2013; 7(4): 663-671.
- Jordheim LP**, Durantel D, Zoulim F, **Dumontet C**. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. *Nat Rev Drug Discov*, 2013; 12(6): 447-464.
- Jordheim LP**, Marton Z, Rhimi M, **Cros-Perrial E**, Lionne C, Peyrottes S, **Dumontet C**, Aghajari N, Chaloin L. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening. *Biochem Pharmacol*, 2013; 85(4): 497-506.
- Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, **Thomas X**, Luquet I, Terre C, Guardiola P, Bene MC, Preudhomme C, Ifrah N, Dombret H. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. *Blood*, 2013; 121(12): 2213-2223.
- Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F,

- Dalle S.** Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. *Br J Dermatol*, 2013; 169(3): 579-586.
- Levy-Sitbon C, Barbe C, Granel-Brocard F, Lipsker D, Aubin F, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Le Clainche A, **Dalle S**, Bernard P, Grange F. Diagnosis and management of melanoma with regional lymph node metastases: a population-based study in France. *J Eur Acad Dermatol Venereol*, 2013; 27(9): 1081-1087.
- Martino A, Sainz J, Manuel Reis R, Moreno V, Buda G, Lesueur F, Marques H, Garcia-Sanz R, Rios R, Stein A, **Dumontet C**, Gemignani F, Maria Rossi A, Landi S, Jurado M, Petrini M, Jamroziak K, Campa D, Canzian F. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. *J Hum Genet*, 2013; 58(3): 155-159.
- Massa AF, **Dalle S**, Thomas L. Subcorneal hematoma. *Ann Dermatol Venereol*, 2013; 140(1): 63-64.
- Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, **Thomas X**, Barraco F, Ducastelle S, Labussiere H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. *Cancer*, 2013; 119(1): 107-114.
- Moulin C, Poulalhon N, Duru G, Debarbieux S, **Dalle S**, Thomas L. Dermoscopy use by French private practice dermatologists: a nationwide survey. *Br J Dermatol*, 2013; 168(1): 74-79.
- Pajares B, Pollan M, Martin M, Mackey JR, Lluch A, Gavila J, Vogel C, Ruiz-Borrego M, Calvo L, Pienkowski T, Rodriguez-Lescure A, Segui MA, **Tredan O**, Anton A, Ramos M, Camara Mdel C, Rodriguez-Martin C, Carrasco E, Alba E. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. *Breast Cancer Res*, 2013; 15(6): R105.
- Patel KJ, **Tredan O**, Tannock IF. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. *Cancer Chemother Pharmacol*, 2013; 72(1): 127-138.
- Pavic M, Pasquet F, Fieschi C, Malphettes M, **Seve P**. Granulomatosis and primary immunodeficiency in the adulthood. *Rev Med Interne*, 2013; 34(3): 154-158.
- Perier-Muzet M, Thomas L, **Dalle S**. Hypopigmented melanoma. *Ann Dermatol Venereol*, 2013; 140(5): 403-404.
- Peron J, Cropet C, **Tredan O**, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C, Blay JY. CD4 lymphopenia to identify end-of-life metastatic cancer patients. *Eur J Cancer*, 2013; 49(5): 1080-1089.
- Plesa A, Chelghoum Y, Mattei E, Labussiere H, Elhamri M, Cannas G, Morisset S, Tagoug I, Michallet M, **Dumontet C**, **Thomas X**. Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia. *World J Stem Cells*, 2013; 5(4): 196-204.
- Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricala C, **Dalle S**, Duval-Modeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, Martin-Denavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ, Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA, Goldstein AM, Akslen LA, Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. *J Med Genet*, 2013; 50(4): 264-270.
- Ricci E, Mattei E, **Dumontet C**, Eaton CL, Hamdy F, van der Pluije G, Cecchini M, Thalmann G, Clezardin P, Colombel M. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. *Prostate*, 2013; 73(16): 1738-1746.

- Saadoun D, Bodaghi B, Bienvenu B, Wechsler B, Sene D, Trad S, Abad S, Cacoub P, Kodjikian L, **Seve P**. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. *Autoimmun Rev*, 2013; 12(7): 774-783.
- Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Micol JB, **Thomas X**, Quesnel B, Celli-Lebras K, Preudhomme C, Terre C, Fenaux P, Chevret S, Castaigne S, Dombret H. Outcome of older patients with acute myeloid leukemia in first relapse. *Am J Hematol*, 2013; 88(9): 758-764.
- Seve P**, Broussolle C, Pavic M. Déficits immunitaires primitifs et cytopénies auto-immunes de l'adulte. *Rev Med Interne*, 2013; 34(3): 148-153.
- Tagoug I**, **Jordheim LP**, **Herveau S**, **Matera EL**, Huber AL, **Chettab K**, Manie S, **Dumontet C**. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors. *Clin Cancer Res*, 2013; 19(13): 3556-3566.
- Tagoug I**, Plesa A, **Dumontet C**. Bortezomib influences the expression of malignant plasma cells membrane antigens. *Eur J Pharmacol*, 2013; 706(1-3): 11-16.
- Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M, Huguet F, Rea D, Delannoy A, Cahn JY, Vernant JP, Ifrah N, Dombret H, **Thomas X**. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. *Biol Blood Marrow Transplant*, 2013; 19(1): 150-155.
- Thomas L, Phan A, Pralong P, Poulalhon N, Debarbieux S, **Dalle S**. Special locations dermoscopy: facial, acral, and nail. *Dermatol Clin*, 2013; 31(4): 615-624.
- Thomas V, Mazard B, Garcia C, Lacan P, **Gagnieu MC**, Joly P. UGT1A1 (TA)_n genotyping in sickle-cell disease: high resolution melting (HRM) curve analysis or direct sequencing, what is the best way? *Clin Chim Acta*, 2013; 424(258-260).
- Touillaud M, Foucaut AM, Berthouze SE, Reynes E, Kempf-Lepine AS, Carretier J, Perol D, Guillemaut S, Chabaud S, Bourne-Branchu V, Perrier L, **Tredan O**, Fervers B, Bachmann P. Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study. *BMJ Open*, 2013; 3(10): e003855.
- Tredan O**, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Menetrier-Caux C. Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. *Eur J Cancer*, 2013; 49(7): 1673-1682.
- Tredan O**, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. *Target Oncol*, 2013; 8(4): 243-251.
- Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengline E, De Gunzburg N, Payet-Bornet D, Lhermitte L, Mossafa H, Lheritier V, Bond J, Huguet F, Buzyn A, Leguay T, Cahn JY, **Thomas X**, Chalandon Y, Delannoy A, Bonmati C, Maury S, Nadel B, Macintyre E, Ifrah N, Dombret H, Asnafi V. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. *J Clin Oncol*, 2013; 31(34): 4333-4342.
- Villani AP, Zaharia D, **Dalle S**, Depaepe L, Balme B, Thomas L. Vemurafenib-induced panniculitis. *Eur J Dermatol*, 2013; 23(2): 258-260.
- Weiler L, Thomas L, **Dalle S**. Pigmented nodular melanoma. *Ann Dermatol Venereol*, 2013; 140(12): 827-828.

2012

- Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, **Dumontet C**, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med*, 2012; 366(19): 1782-1791.
- Bally C, Fadlallah J, Leverger G, Bertrand Y, Robert A, Baruchel A, Guerci A, Recher C, Raffoux E, **Thomas X**, Leblanc T, Idres N, Cassinat B, Vey N, Chomienne C, Dombret H, Sanz M, Fenaux P, Ades L. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. *J Clin Oncol*, 2012; 30(14): 1641-1646.
- Barakat KH, **Jordheim LP**, Perez-Pineiro R, Wishart D, **Dumontet C**, Tuszynski JA. Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. *PLoS One*, 2012; 7(12): e51329.
- Bernard C, Kodjikian L, Bancel B, Isaac S, Broussolle C, **Seve P**. Ocular sarcoidosis: when should labial salivary gland biopsy be performed? *Graefes Arch Clin Exp Ophthalmol*, 2012; 251(3): 855-860.
- Boespflug A**, **Dalle S**, Thomas L. Melanoma mimicking Reed naevus. *Ann Dermatol Venereol*, 2012; 139(12): 857-858.
- Bouaziz A, Le Scannff J, Chapelon-Abric C, Varron L, Khenifer S, Gleizal A, Bentz MH, Barthel A, Valeyre D, **Seve P**. Oral involvement in sarcoidosis: report of 12 cases. *Qjm*, 2012; 105(8): 755-767.
- Bourgne C, Bamdad M, Janel A, Libert F, **Gagnieu MC**, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupre N, Berger MG. Measurement of imatinib uptake by flow cytometry. *Cytometry A*, 2012; 81(11): 996-1004.
- Callens C, **Baleyrier F**, Lengline E, Ben Abdelali R, Petit A, Villarese P, Cieslak A, Minard-Colin V, Rullier A, Moreau A, Baruchel A, Schmitt C, Asnafi V, Bertrand Y, Macintyre E. Clinical Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric T-Cell Lymphoblastic Lymphoma. *J Clin Oncol*, 2012; 30(16): 1966-1973.
- Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Vieira Reis RM, Garcia-Sanz R, Jurado M, Rios R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, Orciuolo E, Gemignani F, Rossi AM, **Dumontet C**, Petrini M, Goldschmidt H, Landi S, Canzian F. Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. *Br J Haematol*, 2012; 157(3): 331-338.
- Cannas G, Pautas C, Raffoux E, Quesnel B, Botton S, Revel T, Reman O, Gardin C, Elhamri M, Boissel N, Fenaux P, Michallet M, Castaigne S, Dombret H, **Thomas X**. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. *Leuk Lymphoma*, 2012; 53(6): 1068-1076.
- Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, **Thomas X**, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. *Lancet*, 2012; 379(9825): 1508-1516.
- Dalle S**. What's new in oncology? *Ann Dermatol Venereol*, 2012; 139 Suppl 5(S217-222).
- Dalle S**, Finet A, Thomas L. Kaposi's sarcoma. *Ann Dermatol Venereol*, 2012; 139(1): 73-74.

- Dalle S**, Parmentier L, Moscarella E, Phan A, Argenziano G, Thomas L. Dermoscopy of merkel cell carcinoma. *Dermatology*, 2012; 224(2): 140-144.
- Detrait M, Dubois V, Sobh M, Morisset S, Tedone N, Labussiere H, Gillis L, Barraco F, Cannas G, Ducastelle S, Fatoum J, **Thomas X**, Chelgoum Y, Nicolini FE, Michallet M. Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens. *Exp Hematol*, 2012; 40(10): 792-799.
- Dufour JF, Le Gallou T, Cordier JF, Aumaitre O, Pinede L, Aslangul E, Pagnoux C, Marie I, Puechal X, Decaux O, Dubois A, Agard C, Mahr A, Como F, Boutemy J, Broussolle C, Guillevin L, **Seve P**, Biennu B. Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. *Medicine (Baltimore)*, 2012; 91(2): 67-74.
- Dupire S, Wemeau M, Debarri H, Pascal L, Hivert B, Willekens C, Boyle E, Manier S, Beatrice T, Onraed B, Faucompre JL, Hennache B, **Dumontet C**, Facon T, Leleu X. Prognostic value of PINI index in patients with multiple myeloma. *Eur J Haematol*, 2012; 88(4): 306-313.
- Ebbo M, Daniel L, Pavic M, **Seve P**, Hamidou M, Andres E, Burtey S, Chiche L, Serratrice J, Longy-Boursier M, Ruivard M, Haroche J, Godeau B, Beucher AB, Berthelot JM, Papo T, Pennaforte JL, Benyamine A, Jourde N, Landron C, Roblot P, Moranne O, Silvain C, Granel B, Bernard F, Veit V, Mazodier K, Bernit E, Rousset H, Boucraut J, Boffa JJ, Weiller PJ, Kaplanski G, Aucouturier P, Harle JR, Schleinitz N. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. *Medicine (Baltimore)*, 2012; 91(1): 49-56.
- Ferry T, Senechal A, **Gagnieu MC**, Boibieux A, Laurent F, Perpoint T, Tod M, Chidiac C. Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection. *J Infect*, 2012; 65(6): 579-582.
- Giebel S, **Thomas X**, Hallbook H, Geissler K, Boiron JM, Huguet F, Koller E, Jaeger U, Smedmyr B, Hellmann A, Holowiecki J. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the EWALL. *Eur J Cancer*, 2012; 48(3): 360-367.
- Gomez-Abreo D, Prost C, Couraud S, Parmeland L, Carret G, Boibieux A, **Gagnieu MC**, Geriniere L, Avrillon V, Souquet PJ. Chronic necrotizing pulmonary aspergillosis following an infection by *Mycobacterium mageritense*. *Rev Mal Respir*, 2012; 29(3): 435-439.
- Goncalves A, **Tredan O**, Villanueva C, **Dumontet C**. Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1). *Bull Cancer*, 2012; 99(12): 1183-1191.
- Grange F, Barbe C, Mas L, Granel-Brocard F, Lipsker D, Aubin F, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, **Dalle S**, Reuter G, Bernard P, Woronoff AS, Arnold F. The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France. *Br J Dermatol*, 2012; 167(6): 1351-1359.
- Hayette S, **Thomas X**, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, Cornillet-Lefebvre P, Plesa A, Huet S, Renneville A, Salles G, Nicolini FE, Magaud JP, Michallet M. High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. *PLoS One*, 2012; 7(12): e51527.
- Hospital MA, **Thomas X**, Castaigne S, Raffoux E, Pautas C, Gardin C, Bourhis JH, Reman O, de Revel T, Terre C, Preudhomme C, Fenaux P, Michallet M, Socie G, Dombret H. Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. *Bone Marrow Transplant*, 2012; 47(11): 1436-1441.

- Joly P, **Gagnieu MC**, Bardel C, Francina A, Pondarre C, Martin C. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. *Am J Hematol*, 2012; 87(5): 534-536.
- Jordheim LP**, Ben Larbi S, Fendrich O, Ducrot C, Bergeron E, **Dumontet C**, Freney J, Doleans-Jordheim A. Gemcitabine is active against clinical multiresistant *Staphylococcus aureus* strains and is synergistic with gentamicin. *Int J Antimicrob Agents*, 2012; 39(5): 444-447.
- Julia F, Thomas L, **Dalle S**. New therapeutical strategies in the treatment of metastatic disease. *Dermatol Ther*, 2012; 25(5): 452-457.
- Kantarjian HM, **Thomas XG**, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysak D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. *J Clin Oncol*, 2012; 30(21): 2670-2677.
- Langrand C, Bihan H, Raverot G, Varron L, Androdias G, Borson-Chazot F, Brue T, Cathebras P, Pinede L, Muller G, Broussolle C, Cotton F, Valeyre D, **Seve P**. Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. *Qjm*, 2012; 105(10): 981-995.
- Lapusan S, Vidriales MB, **Thomas X**, de Botton S, Vekhoff A, Tang R, **Dumontet C**, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, Deangelo DJ, Giles FJ, Marie JP. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. *Invest New Drugs*, 2012; 30(3): 1121-1131.
- Le MP, Solas C, Garraffo R, **Gagnieu MC**, Muret P, Yeni P, Dhiver C, Katlama C, Poizot-Martin I, Durant J, Peytavin G. Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor. *J Antimicrob Chemother*, 2012; 67(11): 2779-2781.
- Le Tourneau C, Kamal M, **Tredan O**, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T, Paoletti X. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. *Target Oncol*, 2012; 7(4): 253-265.
- Manuel M, **Tredan O**, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Menetrier-Caux C. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. *Oncoimmunology*, 2012; 1(4): 432-440.
- Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andre T, **Dumontet C**, Cass CE, **Jordheim LP**, **Matera EL**, Closset J, Salmon I, Deviere J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. *Gastroenterology*, 2012; 143(3): 664-674 e666.
- Martino A, Campa D, Buda G, Sainz J, Garcia-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Rios R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, Landi S, Goldschmidt H, Petrini M, **Dumontet C**, Canzian F, Rossi AM. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. *Leukemia*, 2012; 26(6): 1419-1422.

- Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, Garcia-Sanz R, Lesueur F, Marques H, Moreno V, Jurado M, Rios R, Szemraj-Rogucka Z, Szemraj J, Tjonneland A, Overvad K, Vangstedt AJ, Vogel U, Mikala G, Kadar K, Szombath G, Varkonyi J, Orciuolo E, **Dumontet C**, Gemignani F, Rossi AM, Landi S, Petrini M, Houlston RS, Hemminki K, Canzian F. Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. *Br J Haematol*, 2012; 158(6): 805-809.
- Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, Garcia-Sanz R, Jurado M, Rios R, Szemraj-Rogucka Z, Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S, Rossi AM, **Dumontet C**, Petrini M, Campa D, Canzian F. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). *Int J Oncol*, 2012; 40(3): 625-638.
- Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, **Dalle S**, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita L, Martin L, Crickx B, Joly P, Thomas L, Bressac-de Paillerets B, Avril MF, Demenais F. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. *J Am Acad Dermatol*, 2012; 67(6): 1257-1264.
- Michallet M, Benet T, Sobh M, Kraghel S, El Hamri M, Cannas G, Nicolini FE, Labussiere H, Ducastelle S, Barraco F, **Thomas X**, Chelghoum Y, Nicolle MC, Bienvenu AL, Persat F, De Monbrison F, Picot S, Vanhems P. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. *Eur J Clin Microbiol Infect Dis*, 2012; 31(6): 991-997.
- Miller LM, Huang Yang CP, Xiao H, Isaac S, **Seve P**, **Dumontet C**, Band Horwitz S, Hogue Angeletti R. A label-free mass spectrometry method for relative quantitation of beta-tubulin isotype expression in human tumor tissue. *Proteomics Clin Appl*, 2012; 6(9-10): 502-506.
- Milley S, Bories N, Balme B, Thomas L, **Dalle S**. Indolent CD8+ lymphoid proliferation on the nose. *Ann Dermatol Venereol*, 2012; 139(12): 812-817.
- Pasquet F, Kodjikian L, Mura F, Riviere S, Harroche J, Blanc AP, Chaix F, Oksenhendler E, **Seve P**. Uveitis and common variable immunodeficiency: data from the DEF-I study and literature review. *Ocul Immunol Inflamm*, 2012; 20(3): 163-170.
- Pauwels PJ, **Dumontet C**, Reichert JM, Beck A, Goetsch L, Corvaia N, Klein C, Coiffier B, Teicher B. 7th cancer scientific forum of the canceropole lyon auvergne rhone-alpes: march 20-21, 2012, lyon, france. *MAbs*, 2012; 4(4): 434-444.
- Peron J, **Tredan O**, Ray-Coquard I, Bachelot T, Labidi Galy SI, Favier B, Treilleux I, Guastalla JP. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. *Bull Cancer*, 2012; 99(2): E18-25.
- Peyrouze P, Guihard S, Gardel N, Berthon C, Pottier N, Pigneux A, Cahn JY, Bene MC, Lheritier V, Delabesse E, Macintyre E, **Thomas X**, Dombret H, Ifrah N, Cheek M. Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. *Br J Haematol*, 2012; 159(5): 599-613.
- Poulard C, Treilleux I, Lavergne E, Bouchekioua-Bouzaghrou K, Goddard-Leon S, Chabaud S, **Tredan O**, Corbo L, Le Romancer M. Activation of rapid oestrogen signalling in aggressive human breast cancers. *EMBO Mol Med*, 2012; 4(11): 1200-1213.
- Pralong P, Bathelier E, **Dalle S**, Poulalhon N, Debarbieux S, Thomas L. Dermoscopy of lentigo maligna melanoma: report of 125 cases. *Br J Dermatol*, 2012; 167(2): 280-287.

- Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honore S, Aci-Seche S, Grierson D, Antonipillai J, Li R, Di Pietro A, **Dumontet C**, Braguer D, Florent JC, Knapp S, Bernard O, Lafanechere L. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. *Cancer Res*, 2012; 72(17): 4429-4439.
- Rahmi A, Deshayes E, Maucourt-Boulch D, Varron L, Grange JD, Kodjikian L, **Seve P**. Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled fluorodeoxyglucose positron emission tomography. *Br J Ophthalmol*, 2012; 96(1): 99-103.
- Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, **Seve P**. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. *Ann Oncol*, 2012; 23(1): 86-93.
- Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton S, Revel T, Terre C, Fenaux P, **Thomas X**, Castaigne S, Dombret H, Preudhomme C. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. *Leukemia*, 2012; 26(6): 1247-1254.
- Rhondali W, Perceau E, Berthiller J, Saltel P, Trillet-Lenoir V, **Tredan O**, Coulon JP, Bruera E, Filbet M. Frequency of depression among oncology outpatients and association with other symptoms. *Support Care Cancer*, 2012; 20(11): 2795-2802.
- Rhondali W, Perceau E, Saltel P, Trillet-Lenoir V, Blay JY, Fournel-Federico C, Coulon JP, **Tredan O**, Terra JL, Matillon Y, Bruera E, Filbet M. Depression assessment by oncologists and palliative care physicians. *Palliat Support Care*, 2012; 1-9.
- Rivet C, Caron N, Lachaux A, Morel B, Pracros JP, Francina A, **Gagnieu MC**, Joly P. Association of a glucose-6-phosphate deficiency and a Gilbert syndrome as risk factors for a severe choledocholithiasis in a 2-month-old male infant. *Pediatr Blood Cancer*, 2012; 58(2): 316.
- Romieu I, Touillaud M, Ferrari P, Bignon YJ, Antoun S, Berthouze-Aranda S, Bachmann P, Duclos M, Ninot G, Romieu G, Senesse P, Behrendt J, Balosso J, Pavic M, Kerbrat P, Serin D, **Tredan O**, Ferverts B. Activite physique et survie apres cancer. *Bull Cancer*, 2012; 99(10): 979-994.
- Schmitt C, Bouteille C, Faure C, Mignotte H, **Tredan O**, Bachelot T, Guastalla JP, Arnaud A, Treilleux I, Carrabin N. Adjuvant treatments in breast cancer: interest of completion of axillary dissection in case of micrometastases or isolated tumor cells in sentinel lymph node. *Bull Cancer*, 2012; 99(4): 463-469.
- Seve P**, Varron L, Broussolle C, Denis P, Kodjikian L. Sarcoid-related Uveitis Occurring During Adalimumab Therapy. *Ocul Immunol Inflamm*, 2012; 20(1): 59-60.
- Solas C, **Gagnieu MC**. Evidence-based Therapeutic Drug Monitoring for Efavirenz. *Therapie*, 2012; 66(3): 197-205.
- Thomas X**. Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias. *Blood and Lymphatic Cancer: Targets and Therapy*, 2012; 2(57-76).
- Thomas X**. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. *Expert Opin Investig Drugs*, 2012; 21(6): 871-878.
- Thomas X**. Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy. *World J Stem Cells*, 2012; 4(6): 44-52.
- Thomas X**. DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. *Expert Opin Drug Discov*, 2012; 7(11): 1039-1051.

Thomas X. Intérêt du *priming* dans le traitement de la leucémie aiguë myéloïde. *Hématologie*, 2012; 18(354-362).

Thomas X. Acute myeloid leukemia in the elderly. *International Journal of Hematologic Oncology*, 2012; 1(57-69).

Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P, Preudhomme C, Socie G, Michallet M, Castaigne S, Dombret H. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. *Leuk Res*, 2012; 36(9): 1112-1118.

Varron L, Cottin V, Schott AM, Broussolle C, **Seve P.** Late-onset sarcoidosis: a comparative study. *Medicine (Baltimore)*, 2012; 91(3): 137-143.

Villani AP, Thomas L, **Dalle S.** Pectoral nodule: nodular melanoma. *Ann Dermatol Venereol*, 2012; 139(5): 415-416.

Zeinyeh W, Mahiout Z, Radix S, Lomberget T, Dumoulin A, Barret R, Grenot C, Rocheblave L, **Matera EL, Dumontet C,** Walchshofer N. Progesterone-adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation. *Steroids*, 2012; 77(12): 1177-1191.

2011

Androdias G, Maillet D, Marignier R, Pinede L, Confavreux C, Broussolle C, Vukusic S, **Seve P.** Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. *Neurology*, 2011; 76(13): 1168-1172.

Aouali N, El Btaouri H, **Dumontet C,** Eddabra L, Malagarie-Cazenave S, Madoulet C, Morjani H. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. *Oncol Rep*, 2011; 25(4): 1161-1167.

Arnaud O, Boumendjel A, Geze A, Honorat M, **Matera EL,** Guitton J, Stein WD, Bates SE, Falson P, **Dumontet C,** Di Pietro A, Payen L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan. *Eur J Cancer*, 2011; 47(4): 640-648.

Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, **Tredan O,** Labidi Galy I, Moullet I, Ardisson P, Vincent L, Coeffic D, Dufresne A, Bergerat JP, Ray-Coquard I. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. *Bull Cancer*, 2011; 98(9): 80-89.

Baleyrier F, Domenech C, **Thomas X.** Novel conventional therapies in onco-hematology. *Bull Cancer*, 2011; 98(8): 901-913.

Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P, **Thomas X,** Lepretre S, Huguet F, Vey N, Escoffre-Barbe M, Tavernier E, Reman O, Fegueux N, Turlure P, Rousselot P, Cahn JY, Lheritier V, Chalandon Y, Bene MC, Macintyre E, Dombret H, Ifrah N. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. *Blood*, 2011; 118(19): 5099-5107.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardiere A, Molinie V, Vabres P, **Dalle S,** Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugieres L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R,

- Bahadoran P, Vielh P, Corda E, Blanche H, Zelenika D, Galan P, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fetita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Mateus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature*, 2011; 480(7375): 94-98.
- Caprano V, Zane L, Poncet D, Galia P, Preudhomme C, Bonnefoy-Berard N, Gilson E, **Thomas X**, Elhamri M, Chelghoum Y, Michallet M, Wattel E, Mortreux F, Sibon D. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. *Exp Hematol*, 2011; 39(195-202).
- Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Menetrier-Caux C, **Tredan O**, Goddard-Leon S, Pin JJ, Mignotte H, Bathelemy-Dubois C, Caux C, Lebecque S, Blay JY. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. *BMC Cancer*, 2011; 11(213).
- Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, Mahon FX, **Dumontet C**, Puisieux A, Nicolini FE, Maguer-Satta V. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. *Blood*, 2011; 117(5): 1673-1676.
- Dalle S**, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*, 2011; 365(15): 1448-1449; author reply 1450.
- Dalle S**, **Reslan L**, **Besseyre de Horts T**, **Herveau S**, Herting F, Plesa A, Friess T, Umana P, Klein C, **Dumontet C**. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. *Mol Cancer Ther*, 2011; 10(1): 178-185.
- Dalle S**, Sureda N, Thomas L. Pigmented lesion on the left breast. *Ann Dermatol Venereol*, 2011; 138(1): 69-70.
- Dalle S**, Thomas L, Shear NH. How pharmacogenomics of biological response modifiers will influence clinical response and toxicity in dermatology. *Int J Dermatol*, 2011; 50(1): 114-118.
- Doleans-Jordheim A, Bergeron E, Berezyiat F, Ben-Larbi S, Dumitrescu O, Mazoyer MA, Morfin F, **Dumontet C**, Freney J, **Jordheim LP**. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. *Eur J Clin Microbiol Infect Dis*, 2011; 30(10): 1249-1256.
- Domenech C, **Thomas X**, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D, Bertrand Y. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. *Br J Haematol*, 2011; 153(1): 58-65.
- Dumontet C**. Antitubulin agents. *Bull Cancer*, 2011; 98(11): 1275-1285.
- Gallier F, Lallemand P, Meurillon M, **Jordheim LP**, **Dumontet C**, Perigaud C, Lionne C, Peyrottes S, Chaloin L. Structural Insights into the Inhibition of Cytosolic 5'-Nucleotidase II (cN-II) by Ribonucleoside 5'-Monophosphate Analogues. *PLoS Comput Biol*, 2011; 7(12): e1002295.
- Galy G, Labidi-Galy SI, Perol D, Bachelot T, Ray-Coquard I, **Tredan O**, Biron P, Latour JF, Blay JY, Guastalla JP, Favier B. Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. *Breast Cancer Res Treat*, 2011; 128(1): 187-195.

- Gillibert-Duplantier J, Duthey B, Sisirak V, Salaun D, Gargi T, **Tredan O**, Finetti P, Bertucci F, Birnbaum D, Bendriss-Vermare N, Badache A. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. *Oncogene*, 2011; 31(30): 3516-3524.
- Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard M, **Seve P**, Smail A, Viillard JF, Godeau B, Hermine O, Michel M. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. *Br J Haematol*, 2011; 155(4): 498-508.
- Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, **Dumontet C**, Michallet M, **Thomas X**. Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases. *Leuk Res*, 2011; 35(8): 1027-1031.
- Hage-Sleiman R, Herveau S, Matera EL, Laurier JF, Dumontet C**. Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells. *Mol Cancer Ther*, 2011; 10(2): 303-312.
- Heudel PE, **Tredan O**, Ray-Coquard I, Treilleux I, Guastalla JP, Bachelot T. Antihormonal therapy in breast cancer and mTOR inhibitors. *Bull Cancer*, 2011; 98(12): 1431-1437.
- Honorat M, Falson P, Terreux R, Di Pietro A, **Dumontet C**, Payen L. Multidrug resistance ABC transporter structure predictions by homology modeling approaches. *Curr Drug Metab*, 2011; 12(3): 268-277.
- Honorat M, Mesnier A, Vendrell J, Di Pietro A, Lin V, **Dumontet C**, Cohen P, Payen L. MRP8/ABCC11 expression is regulated by dexamethasone in breast cancer cells and is associated to progesterone receptor status in breast tumors. *Int J Breast Cancer*, 2011; 2011(807380).
- Hunault-Berger M, Leguay T, **Thomas X**, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhedin N, Delannoy A, Lafage-Pochitaloff M, Bene MC, Ifrah N, Dombret H. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. *Haematologica*, 2011; 96(2): 245-252.
- Itzykson R, Gardin C, Pautas C, **Thomas X**, Turlure P, Raffoux E, Terre C, Fenaux P, Castaigne S, Dombret H, Boissel N. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. *Haematologica*, 2011; 96(6): 837-844.
- Jordheim LP**. Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients. *Leuk Res*, 2011; 35(4): 429-430.
- Jordheim LP**, Plesa A, Dreano M, **Cros-Perrial E**, Keime C, **Herveau S**, Demangel D, Vendrell JA, **Dumontet C**. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. *Cancer Chemother Pharmacol*, 2011; 68(1): 97-105.
- Jordheim LP, Seve P, Tredan O, Dumontet C**. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. *Lancet Oncol*, 2011; 12(7): 693-702.
- Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, **Tredan O**, Durand I, Menetrier-Caux C, Caux C, Blay JY, Ray-Coquard I, Bendriss-Vermare N. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. *Cancer Res*, 2011; 71(16): 5423-5434.

- Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, **Thomas X**, Bienvenu AL, Picot S, Nicolle MC, Vanhems P. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. *Med Mycol*, 2011; 49(7): 681-687.
- Nguyen-Dumont T, **Jordheim LP**, Michelon J, Forey N, McKay-Chopin S, Sinilnikova O, Le Calvez-Kelm F, Southey MC, Tavigian SV, Lesueur F. Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2. *BMC Med Genomics*, 2011; 4(39).
- Nguyen AM, **Seve P**, Le Scanff J, Gambrelle J, Fleury J, Broussolle C, Grange JD, Kodjikian L. Clinical and etiological aspects of uveitis: a retrospective study of 121 patients referred to a tertiary centre of ophthalmology. *Rev Med Interne*, 2011; 32(1): 9-16.
- Nicolle MC, Benet T, Thiebaut A, Bienvenu AL, Voirin N, Duclos A, Sobh M, Cannas G, **Thomas X**, Nicolini FE, De Monbrison F, Piens MA, Picot S, Michallet M, Vanhems P. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. *Haematologica*, 2011; 96(11): 1685-1691.
- Phan A, **Dalle S**, Marcilly MC, Bergues JP, Thomas L. Benign dermoscopic parallel ridge pattern variants. *Arch Dermatol*, 2011; 147(5): 634.
- Phan A, **Dalle S**, Thomas L. Hairpin vessels. *Ann Dermatol Venereol*, 2011; 138(6-7): 542-544.
- Plesa A, **Thomas X**, Le QH, Michallet AS, Dubois V, **Dumontet C**, Michallet M. A comparison of flow cytometry detection of minimal residual disease and chimerism kinetics in chronic lymphocytic leukemia patients after allogeneic hematopoietic stem cell transplantation. *J Biomed Sci Eng*, 2011; 4(173-179).
- Puech R, **Gagnieu MC**, Planus C, Charpiat B, Boibieux A, Ferry T, Tod M. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir. *Br J Clin Pharmacol*, 2011; 71(4): 621-623.
- Renneville A, Boissel N, Helevaut N, Nibourel O, Terre C, Pautas C, Gardin C, **Thomas X**, Turlure P, Reman O, Berthon C, Dombret H, Castaigne S, Preudhomme C. Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia. *Leukemia*, 2011; 25(12): 1918-1921.
- Rolin MA, Kodjikian L, Varron L, Nguyen AM, Grange JD, Broussolle C, **Seve P**. Characteristics of uveitis presenting for the first time in the elderly: analysis of 91 patients in a tertiary center. *Ocular Immunol Inflamm*, 2011; 19(219-226).
- Seve P**, Lega JC. Kawasaki disease in adult patients. *Rev Med Interne*, 2011; 32(1): 17-25.
- Seve P**, Pavic M. Sarcoidosis: What's new in 2010 for internists? *Rev Med Interne*, 2011; 32(2): 71-72.
- Sureda N, Phan A, Poulalhon N, Balme B, **Dalle S**, Thomas L. Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review. *Br J Dermatol*, 2011; 165(4): 852-858.
- Sureda N, Thomas L, Bathelier E, Balme B, Depaepe L, **Dalle S**. Bullous lymphomatoid papulosis. *Clin Exp Dermatol*, 2011; 36(7): 800-801.
- Tagoug I**, **Sauty De Chalon A**, **Dumontet C**. Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. *PLoS One*, 2011; 6(7): e22641.
- Thomas X**. Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia? *Bull Cancer*, 2011; 98(7): 761-767.

- Thomas X** Chapter 16: Induction therapy in adult acute lymphoblastic leukemia. *In*: S. Faderl and H. Kantarjian (eds.), *Leukemias: Principles and Practice of Therapy*, 1st edition, pp. 193-216: Blackwell Publishing Ltd., 2011.
- Thomas X**, Chelghoum Y. Promyelocytic sarcoma of the sternum: a case report and review of the literature. *Korean J Hematol*, 2011; 46(1): 52-56.
- Thomas X**, Chelghoum Y. Lenalidomide in elderly acute myeloid leukemia (AML) patients with deletion 5q [del(5q)]. *Blood e-letter*, 2011;
- Thomas X**, Chelghoum Y, Cannas G, Elhamri M, Labussiere H, Tigaud I, Ducastelle S, Nicolini F, **Dumontet C**, Michallet M. Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making? *Clin Lymphoma Myeloma Leuk*, 2011; 11(4): 342-349.
- Thomas X**, Chelghoum Y, Fanari N, Cannas G. Serum 25-hydroxyvitamin D levels are associated with prognosis in hematological malignancies. *Hematology*, 2011; 16(5): 278-283.
- Thomas X**, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C, Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H. Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. *Blood*, 2011; 118(7): 1754-1762.
- Tod M, Goutelle S, **Gagnieu MC**. Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. *Clin Pharmacol Ther*, 2011; 90(4): 582-587.
- Tredan O**, Ray-Coquard I, Arnaud A, Racadot S, Guastalla JP. Cervix cancer and corpus cancer of the uterus. *Rev Prat*, 2011; 61(10): 1435-1442.
- Tredan O**, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, Perol D, Saba C, Quiblier F, Blay JY, Bachelot T. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. *BMC Cancer*, 2011; 11(95).
- Vallin M, Guillaud O, Morard I, **Gagnieu MC**, Mentha G, Adham M, Morelon E, Boillot O, Giostra E, Dumortier J. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. *Clin Transplant*, 2011; 25(4): 660-669.
- Varron L, Abad S, Kodjikian L, **Seve P**. Sarcoid uveitis: Diagnostic and therapeutic update. *Rev Med Interne*, 2011; 32(2): 86-92.
- Varron L, Vignes S, Green L, Morelec I, Broussolle C, **Seve P**. Recurrent lymphangiectasia of the left supraclavicular fossa: an unusual cause of paroxysmic swelling. *Arch Dermatol*, 2011; 147(11): 1337-1338.